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Original Article
Capsular contracture in implant based breast reconstruction—the 
effect of porcine acellular dermal matrix
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Background: Irradiation of implant-based breast reconstructions (BR) is known to increase capsular 
contracture (CC) rates on average by 4-fold over non-irradiated reconstructions. The use of acellular 
dermal matrix (ADM) has been associated with lower CC rates in non-irradiated reconstructions (0-3%). 
Experimental and clinical studies suggest that ADM may also reduce CC rates in irradiated breasts. The aim 
of this study was to evaluate CC rates in non-irradiated and irradiated one- and two-stage BRs performed 
with the assistance of porcine ADM (PADM).
Methods: A single centre, retrospective, cohort study was designed from December 2008 to October 2012. 
A total of 200 immediate implant-based BRs were performed using PADM for inferior pole reinforcement. 
We included non-irradiated BR with a minimum follow up of 6 month from primary surgery (one stage) or 
from explantation of expander and implantation of the definitive implant (two stage). Of the postoperatively 
irradiated BR we included patients with 1 year or more follow up time from termination of radiotherapy. 
CC was graded using the conventional Spear-Baker classification and modified version for irradiated BR. 
According to the literature Grade III and IV CC were defined as clinically significant CC.
Results: Of 200 BRs with PADM, 122 were included in this study (84 non-irradiated and 38 irradiated). 
Sixty-five BR were one stage and 57 were two stage BR. Grade III/IV CC was remarkable low in non-
irradiated (6%) and irradiated BR (13%). There was a non-significant trend to increased Grade III and IV 
CC in irradiated BR vs. non-irradiated BR (13% vs. 6%, P=0.216). In this study follow up time (P<0.001) 
and the stage of ADM reconstruction (two vs. one stage, P=0.022) were significant risk factors for occurrence 
of grade III/IV CC on univariate analysis and remained significant for the follow up time (P=0.013) and 
remarkable for the stages (P=0.093) in multivariate analysis. 
Conclusions: Our data support the current clinical evidence that ADM use in implant-based BR is 
associated with a reduced risk of CC when compared to the standard submuscular techniques in literature. 
The reduced risk is maintained in the setting of radiotherapy. Two stage procedures in our study population 
showed increased grade III/IV CC compared to one stage procedures with or without exposure to radiation.
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Introduction
Acellular dermal matrices (ADMs) are increasingly used in 
immediate implant-based breast reconstruction (BR) (1). 
Although originally intended to provide support and coverage of 
the breast lower pole, growing evidence suggests that ADM use 
may also mitigate the risk of capsular contracture (CC) (2-5).
CC is a significant complication in implant-based 
reconstructions, with a cumulative incidence of 6–18%, 
over a 3–6-year period reported in core clinical studies of 
implant manufacturers (6-8). In contrast, ADM-assisted 
reconstructions have consistently been associated with 
CC rates of <5%, albeit a shorter follow-up period of 
0.6–2.4-year (9-15) is reported. Mechanistic studies in 
animal models as well as human histopathologic studies 
suggest a reduction or delay in capsule formation in 
the presence of ADM as a possible explanation for the 
reduced occurrence of CC (5,16-18).
External beam radiotherapy (EBRT) is a recognised risk 
factor for CC and CC rates of 15–50% have been reported 
in standard submuscular reconstructions without the use 
of ADM (19-24). Given the rising trend of immediate 
implant-based BR following mastectomy before the need 
for radiotherapy is fully determined, there is an increasing 
need for novel measures to reduce CC risk in this patient 
group. Because ADMs appear to mitigate the risk of CC, 
the natural question is whether these matrices also reduce 
the risk in the setting of radiotherapy. Data on the incidence 
of CC in the setting of radiotherapy in ADM-assisted 
reconstructions are, however, limited with short follow 
up times (9,12,13,18,24-28). Salzberg recently published 
a long-term follow-up (13 years) with low CC rate even 
after radiotherapy (1.9%) when ADM is used in one-stage 
implant based BR (28). The purpose of this study was to 
compare CC rates in non-irradiated and irradiated porcine 
acellular dermal matrix (PADM)-assisted one- and two-
stage immediate implant-based BR.
Methods
This is a retrospective cohort study performed from 
December 2008 to October 2012 at Guy’s and St Thomas’s 
Hospitals, London. During this period, 149 patients (200 
reconstructions) who underwent immediate, implant-
based BR with the assistance of PADM with or without 
radiotherapy were identified. 
Our operative technique of using PADM (StratticeTM, 
LifeCell Corporation, Branchburg, NJ, USA) has been 
previously described (29). Briefly, mastectomy was 
performed via a skin-sparing or nipple-sparing approach 
by breast surgeons in attendance of the plastic surgeon. 
Following mastectomy, the pectoralis major muscle was 
elevated and a subpectoral pocket was created using standard 
techniques. PADM was rinsed in antibiotic solution prior to 
insertion. The inferior border of PADM was sutured to the 
chest wall along the inframammary fold, extending medially 
and laterally. A silicone cohesive gel implant (one stage) 
or tissue expander (two stage) was placed into the pocket 
and the upper border of PADM was sutured to the inferior 
border of the freed pectoralis muscle in a sublay technique 
resulting in closure of the pocket. Extra care was taken to 
avoid creases or folds of the PADM and dead space between 
the PADM and host tissue. Two drains were placed, one 
in the pocket and the other subcutaneously along the 
inframammary fold. If axillary clearance was performed, a 
third drain was placed in the axilla. All drains were removed 
after drainage was reduced to <30 mL over 24 h. Typically, 
prophylactic intravenous antibiotics were commenced 30 
min prior to surgery, which was followed by 3 additional 
intravenous doses and then switched to oral antibiotics, 
which were continued for 5 days. 
In one stage procedures, a definitive implant was placed 
at the same operative step as mastectomy was performed. 
In the two stage procedures, an expander was placed at 
first step (critical skin flap perfusion, surgeons’ preference, 
patients wish for larger breast size), followed by weeks of 
expansion to the desired breast size. 
Adjuvant anthracycline or anthracycline/taxane based 
chemotherapy given over 6–8 cycles generally started 
4 weeks postoperatively (one stage) or after completion of 
expansion (two stage) when no wound healing problems 
were present. In a neoadjuvant chemotherapy setting a 
time slot of 3–6 weeks was maintained before mastectomy 
and reconstruction. Adjuvant radiotherapy was initiated 
at a minimum of 3 weeks following completion of 
chemotherapy or surgery. External beam irradiation to 
the chest wall comprised 40 Gy in 15 fractions delivered 
using tangential 6 and/or 10MV photon beams. In two 
stage procedures EBRT and chemotherapy were started 
after completion of expansion and the exchange for the 
definitive implant was performed after completion of 
chemo/radiotherapy in all cases.
We included patients with a minimum postoperative 
follow up of 6 months after insertion of implant in one-
stage procedures and after exchange of expander for 
definitive implant in two-stage procedures in non-irradiated 
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BR. Irradiated BR were included with a minimum follow up 
time of one year from completion of radiotherapy. 
Data collection and analysis
Patient demographic data including age, body mass index, 
diabetes, current tobacco use, chemotherapy (neoadjuvant 
or adjuvant) and radiotherapy use were collected from 
hospital records. Clinical examination and classification 
of CC was performed in the outpatient clinic by the first 
author only (AML who was not involved in the surgery). 
CC was graded using the conventional Spear-Baker 
classification for non-irradiated breasts (30). A modified 
version of this classification in irradiated breasts (26). Grade 
III and IV CC were determined as clinically significant CC 
according to the literature.
All complications occurring during the follow-up 
period specified above were recorded. Complications and 
Grade III/IV CC rates were analysed using a Generalized 
Estimating Equations (GEE) model (31). This model 
accounts for potential intrapatient correlation of results. If 
due to low cell sizes a GEE model could not be fitted rates 
were compared using Fisher’s exact test. Exact confidence 
intervals for rates and rate differences were calculated 
assuming a binomial distribution. A value of P<0.05 was 
considered significant.
Results
Over a 4-year period, 149 patients underwent 200 
PADM-assisted immediate implant-based BR. A total of 
177 reconstructions met our inclusion criteria (>6-month 
follow-up after the last procedure in non-irradiated 
breasts and >1-year follow-up after radiotherapy in 
irradiated breasts). Of the 177 reconstructions, 55 
were excluded because 28 were switched to autologous 
reconstruction or had implant loss (infections, skin flap 
necrosis, patients wish) and 27 were lost to follow up. 
The remaining 122 reconstructions were included in 
this study. Eighty mastectomies were performed for 
oncological reason, 42 were risk-reducing mastectomies 
in BRCA positive patients. Sixty-five were one-stage 
(direct to implant) and 57 two-stage procedures. In 
84 BR, no radiotherapy had to be administered, 38 
BR underwent postoperative radiotherapy. Patient 
demographics are summarized in Table 1.
Patients were followed for a median of 26.5 months 
(range, 6–51 months). During this time, complications 
occurred in 32 breasts for a total complication rate of 26%. 
Complications included, 14 seromas (11.5%), 6 haematomas 
(7.3%), and 10 grade III/IV CC (8.2%) and 3 others (2.4%) 
(1 small skin necrosis, 1 implant rotation, 1 moderate 
wound healing problem).
When stratified by radiotherapy use, total complication 
rate and CC rate was numerically higher 12 (31.6%) vs. 20 
(23.8%), but not significantly higher (P=0.535), in irradiated 
breasts (Table 2). Patient demographics (age) and clinical 
characteristics (BMI, tobacco use, diabetes, breast weight) 
were similar between the irradiated and non-irradiated 
groups (Table 3). Mean follow up was significantly longer 
(31.8 months) in irradiated versus non-irradiated breasts 
(22.2 months) due to the inclusion criteria (follow up time in 
irradiated BR at least >1 year of termination of radiotherapy, 
compared to minimum 6 months postoperative in non-
irradiated BR). A significantly higher percentage of breasts 
in the irradiated group had mastectomy weights >600 g. 
Treatment with neoadjuvant and adjuvant chemotherapy was 
also significantly higher in irradiated breasts (Table 3). 
When stratified by one- vs. two-stage procedures, 
overall complications were similar between the groups 
while seroma and hematoma were numerically higher and 
Table 1 Patient demographics and clinical characteristics
Variables Data
Patients 96
Breast reconstructions (BR) 122
Follow up, median [range] (months) 26.5 [6–51]
Age, mean ± SD (years) 47.5±11.4
BMI, mean ± SD (kg/m2) 25.4±4.4
Mastectomy
Breast weight available 91
Breast weight >600 g (% of BR) 31 (34.0)
Current tobacco use (% of patients) 12 (12.5) 
Diabetes (% of patients) 2 (2.2) 
Neoadjuvant chemotherapy (% of patients) 12 (12.5)
Adjuvant chemotherapy (% of patients) 35 (36.5)
Chemotherapy for contralateral breast cancer 
(% of patients)
3 (3.2)
Irradiation (% of BR) 38 (31.5)
No Irradiation (% of BR) 84 (68.9)
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CC significantly lower in one-stage procedures (1.5% 
vs. 15.8%, P=0.022) (Table 4). There was no difference in 
patient demographics and clinical characteristics between 
the two groups, except for adjuvant chemotherapy and 
adjuvant radiotherapy use, which was significantly higher 
in two-stage procedures (Table 5). Average follow-up was 
significantly longer in two-stage procedures (31.0 vs. 
21.6 months, P<0.001) because of increasing numbers of 
one-stage procedures toward the end of the study period. 
The higher rate of CC in two-stage procedures was seen in 
Table 2 Complications in irradiated versus non-irradiated breasts
Complication Non-irradiated breasts (n=84) (%) Irradiated breasts (n=38) (%) P value (univariate GEE model)
Total complication 20 (23.8) 12* (31.6) 0.535
Seroma 10 (11.9) 4 (10.5) 0.689
Haematoma 4 (4.8) 2 (5.3) 0.903
CC (grade III/IV) 5 (6.0) 5 (13.2) 0.216
Other 2 (2.4) 1 (2.6) 0.553
*, haematoma and seroma occurred in one breast. CC, capsular contracture.
Table 3 Patient demographics and clinical characteristics stratified by radiotherapy use
Demographics, clinical characteristics Non-irradiated (patients =58; breasts =84) Irradiated (patients =38; breasts =38) P value
Follow up, median [range] (months) 21.0 [6–51] 33.3 [12–47] <0.001*
Age, mean ± SD (years) 48.7±11.9 46.7±10.5 0.208**
BMI, mean ± SD (kg/m2) 24.9±3.2 26.1±5.5 0.221**
Mastectomy
Breast weight available 64 27
Breast weight >600 g (% of breasts) 17 (26.6) 14 (51.9) 0.029***
Current tobacco use (% of patients) 6 (10.3) 6 (15.6) 0.534***
Diabetes (% of patients) 1 (1.7) 1 (2.6) 1.000***
Neoadjuvant chemotherapy (% of patients) 1 (1.7) 11 (29.0) <0.001***
Adjuvant chemotherapy (% of patients) 13 (22.4) 22 (57.9) <0.001***
*, Wilcoxon rank sum test; **, t-test; ***, Fisher’s exact test.
Table 4 Complications in one versus two-stage procedures
Complication One stage breasts (n=65) (%) Two stage breasts (n=57) (%) P value (univariate GEE model)
Total complication 17 (26.2) 15* (26.3) 0.837
Seroma 10 (15.4) 4 (7.0) 0.179
Haematoma 4 (6.2) 2 (3.5) 0.501
CC (grade III/IV) 1 (1.5) 9 (15.8) 0.022
Other 2 (3.1) 1 (1.8) 0.924
*, haematoma and seroma occurred in one breast. CC, capsular contracture. 
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both irradiated and non-irradiated breasts (Table 6). 
The univariate analysis for exploration of risk factors 
of the occurrence of clinical CC (Grade III/IV) showed 
two significant risk factors in this study: follow up time 
(P<0.001) and stages (P=0.022) (Table 7). Irradiation and 
chemotherapy did not point out as significant risk factors, 
neither BMI, age, breast size or smoking. 
On the multivariate analysis combining follow up time 
and the stages (Table 8), the follow up time kept a significant 
(P=0.013) influence on occurrence of CC in this study. 
The two-stage procedure remained a strong risk factor for 
development of CC (P=0.093)
Discussion
CC is a significant complication of implant-based, BR 
with unpredictable occurrence and recurrence despite 
treatment. The aetiology of CC remains unclear but 
recent evidence suggests a bacterial infection trigger for 
Table 5 Patient demographics and clinical characteristics stratified by one- versus two-stage procedures
Demographics, clinical characteristics One stage (breasts =65; patients =46) Two stage (breasts =57; patients =50) P value
Follow up, median [range] (months) 21.6 [7–51] 31.0 [6–47] <0.001*
Age, mean ± SD (years) 47.6±10.9 47.4±12.0 0.922**
BMI, mean ± SD (kg/m2) 24.7±3.3 26.0±5.0 0.173**
Mastectomy 0.081***
Breast weight available 50 41
Breast weight >600 g (% of breasts) 13 (26.0) 18 (43.9)
Current tobacco use (% of patients) 5 (10.9) 7 (14.0) 0.762***
Diabetes (% of patients) 0 2 (4.0) 0.496***
Neoadjuvant chemotherapy (% of patients) 5 (10.9) 7 (14.0) 0.762***
Adjuvant chemotherapy (% of patients) 11 (23.9) 24 (48.0) 0.020**
Adjuvant radiotherapy 11 (23.9) 27 (54.0) 0.003***
*, Wilcoxon rank sum test; **, t-test; ***, Fisher’s exact test.
Table 6 Grade III/IV capsular contracture stratified by irradiation 
and stage 
Statistics
Nonirradiated Irradiated
One stage Two stage One stage Two stage
Breast 54 30 11 27
Rate of CC (%) 1.9 13.3 0.0 18.5
95% CI (%) 0.0–9.9 3.8–30.7 0.0–28.5 6.3–38.1
P value 0.070* 0.295**
*, GEE model; **, Fisher’s exact test.
Table 7 Exploration of risk factors for the occurrence of grade III/
IV capsular contracture (grade III/IV) using univariate GEE model 
analyses
Risk factor Odds Ratio 95% CI P value
Stage (two vs. one stage) 11.74 1.43–96.12 0.022
Irradiation (yes vs. no) 2.29 0.62–8.49 0.216
Chemotherapy (yes vs. no) 2.00 0.53–7.51 0.304
Follow-up 1.11 1.05–1.17 <0.001
Age 1.02 0.97–1.07 0.471
BMI 1.11 0.96–1.27 0.145
Breast weight 1.001 0.999–1.003 0.265
Smoker (yes vs. no) 0.91 0.11–7.72 0.927
Table 8 Exploration of risk factors for the occurrence of grade III/
IV capsular contracture (grade III/IV) using multivariate GEE 
model analyses for factors significant in univariate models
Risk factor Odds ratio 95% CI P value
Stage (two vs. one stage) 6.55 0.73–58.52 0.093
Follow-up 1.10 1.02–1.18 0.013
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the inflammatory response that characterizes CC (32). 
There are no known specific preventive measures for 
CC but technical considerations such as antibiotic breast 
pocket irrigation (33), use of textured implants (34), and 
subpectoral placement of implants (35) have all been 
shown to reduce the risk of contracture. A growing body 
of evidence indicates that the use of ADM may provide 
another means to reduce the risk of CC (2-5,9-15). 
Radiotherapy is considered as one of the most important 
factors that augment the risk of CC. In the absence of 
radiotherapy, the rate of clinically significant CC (Grade 
III/IV) varies from 0–20% in standard submuscular BR 
without the use of ADM. In the presence of radiotherapy, 
the rate increases to 15–50%, which is an approximately 
4-fold increase (19-24). The need for subsequent irradiation 
is, thus, often considered as a relative contraindication for 
implant-based BR. Radiation-induced CC is undoubtedly 
detrimental to the aesthetic appearance of the implant-
enhanced breast.
Data on the rate of CC in ADM-assisted reconstructions in 
the setting of radiotherapy are limited. In the published studies 
the contracture rate varied between 0–60% (9,12,13,18,24-28) 
and 0–3% for non-irradiated breasts (12,25,26). 
In the present study using PADM for lower pole 
reinforcement, we found a low rate of clinically significant 
CC (grade III/IV) in both non-irradiated (6%) and 
irradiated (13%) immediate implant-based BR, although 
the rate was 2-fold higher in the irradiated group. The 
median follow up was almost 2 years in the non-irradiated 
group and almost 3 years in the irradiated group, suggesting 
that the low risk of CC with ADM use is at least maintained 
over medium term. 
The findings of this study have been attenuated by the 
fact that the longer follow up time after primary surgery (one 
stage) or after exchange of the expander for definitive implant 
(two stage) the higher risk for occurrence of high grade CC 
was found. This fact suggests a further increase in CC in long 
term. On the other hand, Salzberg in his recent study found 
CC, when ADM was used, did appear during the first 2 years 
postoperatively and was described as an early event in ADM 
based reconstructions (28). Nevertheless, there is a need for 
more large series with long follow up times and comparison 
to non-ADM reconstructions to strengthen the findings.
Regardless a significant increase in occurrence of 
CC was found in expander based traditional (two stage) 
procedures compared to direct to implant (one stage) 
reconstructions (P=0.022). In the multivariate analysis, 
this trend was maintained after clearing for the effect 
of follow up time (P=0.093) and hasn’t been described 
in literature to our knowledge. Two-stage procedures 
provide the opportunity to perform capsulectomy at the 
time of exchange of the expander (which eventually also 
was exposed to chemo/radiotherapy) for the definitive 
implant. Therefore, it is generally believed that two stage 
procedures are associated with a lower incidence of CC. 
Our results seem to contradict these general expectations. 
It is imaginable that tissue expansion in itself increases scar 
tissue/capsule formation similar to callus formation during 
healing of fractures. The repetitive trauma of expansion, 
tension and weakening of the skin flap may have created 
an environment for an exaggerated tissue response to the 
implant, which may explain the higher rate of contracture 
in our series. 
This study is limited by its retrospective nature, the 
small number of reconstructions in the irradiated group, 
and the absence of a non-ADM group and the relatively 
short follow up times. Nevertheless, compared to published 
CC rates with similar follow up times, our rates are 
substantially lower, suggesting that PADM use is associated 
with a reduced or delayed risk for CC and could tribute 
to longevity of the reconstruction result. In addition, 
this study points out the importance of follow up times 
concerning occurrence of CC and suspects expansion to 
trigger CC.
Conclusions
Our data support the current clinical evidence that ADM 
use in implant-based BR is associated with a reduced risk of 
CC when compared to the standard submuscular techniques 
in literature. The reduced risk is maintained in the setting 
of radiotherapy. Two stage procedures in our study 
population showed increased grade III/IV CC compared to 
one stage procedures with or without exposure to radiation.
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